p53 gene (Gendicine®) and embolisation overcame recurrent hepatocellular carcinoma

Yongsong Guan ^1*, Yuan Liu ¹, Xiangping Zhou ¹, Xiao Li ¹, Qing He ¹ and Long Sun ¹

¹ West China Hospital of Sichuan University, China

^* To whom correspondence should be addressed. E-mail: yongsongguan{at}yahoo.com.

Accepted 28 April 2005

Abstract

Transcatheter arterial chemoembolization (TACE) has become the standard treatment for unresectable hepatocellular carcinoma (HCC). 1-4 But this method is often unsuccessful. The p53 gene, which is present as a mutant form in many human tumors, is known to have broad- spectrum anti-tumor effects when expressed normally. In this study, we report a 23-year-old patient with recurrent HCC, who was treated with p53 gene (Gendicine®, Shenzhen Sibiono Gentech, China) combining TACE, which resulted in good clinical prognosis.

Keywords: arterial, chemoembolization, hepatocellular carcinoma, p53 gene, transcatheter

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Digest

Robin Spiller
Gut 2005 54: 1209. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Su, C., Cao, H., Tan, S., Huang, Y., Jia, X., Jiang, L., Wang, K., Chen, Y., Long, J., Liu, X., Wu, M., Wu, X., Qian, Q. (2008). Toxicology Profiles of a Novel p53-Armed Replication-Competent Oncolytic Adenovirus in Rodents, Felids, and Nonhuman Primates. Toxicol Sci 106: 242-250 [Abstract] [Full Text]